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OBJECTIVE—Adiponectin is an adipocyte-derived hormone
that sensitizes insulin and improves energy metabolism in tissues.
This study was designed to investigate the direct regulatory effects
of adiponectin on lipid metabolism in adipocytes.
RESEARCH DESIGN AND METHODS—Basal and hormone-
stimulated lipolysis were comparatively analyzed using white
adipose tissues or primary adipocytes from adiponectin gene
knockout and control mice. To further study the underlying
mechanisms through which adiponectin suppresses lipolysis,
cultured 3T3-L1 adipocytes and adenovirus-mediated gene trans-
duction were used.
RESULTS—Signiﬁcantly increased lipolysis was observed in
both adiponectin gene knockout mice and primary adipocytes
from these mice. Hormone-stimulated glycerol release was in-
hibited in adiponectin-treated adipocytes. Adiponectin suppressed
hormone-sensitive lipase activation without altering adipose tri-
glyceride lipase and CGI-58 expression in adipocytes. Moreover,
adiponectin reduced protein levels of the type 2 regulatory subunit
RIIa of protein kinase A by reducing its protein stability. Ectopic
expression of RIIa abolished the inhibitory effects of adiponectin
on lipolysis in adipocytes.
CONCLUSIONS—This study demonstrates that adiponectin
inhibits lipolysis in adipocytes and reveals a novel function of
adiponectin in lipid metabolism in adipocytes. Diabetes 60:1519–
1527, 2011
W
hite adipose tissue (WAT) mass is mainly
determined by adipocyte number and size. It
is logical to assume that increase of adipo-
cyte number and size expands adipose tissue
mass and results in obesity. However, a study demon-
strated that adipocyte populations are determined during
the ﬁrst 2 decades of life and are stable in adults (1), sug-
gesting that lipid storage should play a key role in adult
obesity. Lipid storage is dynamic and mainly controlled by
two opposing processes: lipogenesis and lipolysis.
Adiponectin is an adipocyte-secreted hormone that en-
hances insulin sensitivity. Adiponectin gene expression
and blood levels are decreased in obese adults and
animal models (2). Adiponectin transgenic female FVB
mice exhibit increased body weight and fat tissue mass (3).
Furthermore, modestly increasing serum adiponectin com-
pletely rescued the diabetic phenotype in ob/ob mice with
signiﬁcant expansion of adipose tissue (4). These studies
suggest that adiponectin may regulate lipid metabolism in
adipocytes through a direct or indirect mechanism.
We describe a novel function of adiponectin in lipid
metabolism in adipocytes. Our results show that adipo-
nectin inhibits lipolysis by suppressing protein kinase A
(PKA)–mediated hormone-sensitive lipase (HSL) activation.
In addition, adiponectin reduces the PKA RIIa regulatory
subunit protein level by increasing its protein degradation
in adipocytes.
RESEARCH DESIGN AND METHODS
Seedetailedinformationonmaterials,virusconstruction,quantitative PCR,and
adipocyte area measurement in the Supplementary Methods.
Experimental animals. Adipoq
2/2 mice were created as previously de-
scribed (5) on the 129/SvEv genetic background and had been back-crossed to
C57BL/6 for ﬁve generations. Male mice were used. The experiments using
mouse models were carried out under the Association for Assessment and
Accreditation of Laboratory Animal Care guidelines with approval of the An-
imal Care and Use Committee. For some animal studies, 1 3 10
9 pfu of puriﬁed
adenovirus vectors was injected into the mouse tail vein (6).
Cell culture. 3T3-L1 and 3T3-L1CARD1 cells and induction of adipocyte dif-
ferentiation were described in a previous publication (7). OP9 adipocyte dif-
ferentiation was induced using KnockOut SR (8). Although both 3T3-L1 and
OP9 adipocytes secrete adiponectin into the medium, adiponectin in overnight
cultured medium accumulated only to ;0.1% of mouse serum adiponectin.
Therefore, co-culture or conditioned medium was used to increase adipo-
nectin protein levels. For co-culture, adipocytes were cultured in the outside
well of the BD Biosciences (Franklin Lakes, NJ) transwell co-culture system,
and FAO cells were grown on the protein and cytokine-permeable membrane
of the insert well. FAO cells were transduced with adenovirus encoding mouse
adiponectin (Ad-Acrp30) or green ﬂuorescent protein (GFP) for 12 h in a
regular 6-well plate, and then the inserts with transduced FAO cells were
washed and transferred to the co-culture plates with differentiated adipocytes
in the bottom wells. This system allows increase of medium adiponectin levels
(;40% of mouse serum adiponectin) without physical interaction between
3T3-L1 adipocytes and FAO cells. In a separate setting, conditioned medium
from Ad-Acrp30–transduced FAO cells was collected and used for increasing
adiponectin levels in some of the studies, as indicated in ﬁgure legends. For
hormone-stimulated lipolysis, Bt2-cAMP (100 mmol/L) was added to culture
medium and cells were incubated for 1 h. Total protein was used for certain
protein or protein phosphorylation measurements using Western blots. For
PKA RIIa protein half-life measurement, the adipocytes were pretreated with
adiponectin overnight. Then, cycloheximide (100 mg/mL) was used to inhibit
protein synthesis.
Lipolysis assay. For the in vivo lipolysis assays, the selective b3-adrenergic
agonist BRL37344 was injected i.p. into mice at 5 mg/g body wt (9). Blood
samples were collected 0, 10, and 20 min after the injection. For the lipolysis
assay of adipose explants, ;20 mg of epididymal adipose tissue explants were
cultured in Dulbecco’s modiﬁed Eagle’s medium with 0.5% fatty acid–free BSA
(10). BRL37344 was added to the medium at 50 ng/mL. The culture tubes were
shaken at 400 rpm. The medium samples were collected 30, 60, 120, and 180
min after adding BRL37344. The level of free fatty acid (FFA) or glycerol was
normalized to the weight of adipose explants. For primary adipocyte lipolysis
assays, adipocytes were prepared from epididymal fat using collagenase with
an optimized procedure (11,12). Brieﬂy, epididymal fat tissue was minced and
digested in a Krebs-Ringer bicarbonate (KRB) buffer (pH 7.4) supplemented
with 3% fatty acid–free BSA fraction V, 0.5 mmol/L adenosine, and 1 mg/mL
type I collagenase. After 40-min digestion and three washes, isolated adi-
pocytes were resuspended in KRB supplemented with 5 mmol/L glucose and
3% fatty acid–free BSA. Suspended adipocytes (;6,000 cells) were used for
a lipolysis assay in 400 mL KRB buffer plus 3% fatty acid–free BSA, 1 unit/mL
adenosine deaminase, and 100 nmol/L (-)-N
6-(2-phenyl-isopropyl)-adenosine
(basal only) with or without BRL37344 (50 ng/mL). After 1-h incubation at
37°C, 200 mL of infranatant was removed and stored at 220°C. Bt2-cAMP
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ORIGINAL ARTICLE(100 mmol/L) was used for stimulating 3T3-L1 adipocyte lipolysis. Serum free
glycerol and glycerol released from fat explants were measured using a free-
glycerol kit (Sigma-Aldrich Co., St. Louis, MO). Glycerol in the assay media of
primary and 3T3-L1 adipocytes was measured using bioluminescence, which is
very sensitive and especially well adapted when only small amounts of adipose
tissue or cells are available (13,14).
Statistical analysis. Data are expressed as mean 6 SEM. Statistical analysis
was performed using the Student t test or ANOVA, followed by contrast test.
Differences were considered signiﬁcant at P , 0.05.
RESULTS
Adiponectin knockout male mice have small fat mass
and are resistant to high-fat diet–induced obesity. To
study the effects of adiponectin on lipid metabolism in
adipocytes, Adipoq
2/2 mice were used. Consistent with
previous studies (5,15), there were no signiﬁcant differ-
ences of body weights between Adipoq
2/2 and wild-type
(WT) littermate controls when the mice were fed normal
chow (data not shown). However, body fat percentage of
Adipoq
2/2 mice was signiﬁcantly lower than that of WT
mice (Fig. 1A). Epididymal fat mass was also signiﬁcantly
smaller in Adipoq
2/2 male mice (0.26 6 0.02 vs. 0.42 6
0.04 g; vs. WT, P , 0.05, n = 10). Adipocyte cross-sectional
areas of ﬁxed epididymal fat of Adipoq
2/2 mice were 20%
smaller than those of WT control mice (Supplementary
Fig. 1A). When mice were fed a 60% (calorie) high-fat diet
for 8 weeks, Adipoq
2/2 mice gained remarkably less body
weight and adipose tissue mass and had smaller adipocyte
area (Fig. 1B and C, Supplementary Fig. 1B). Similar to
previous studies (5,16), high-fat diet induced more severe
insulin resistance in Adipoq
2/2 mice (data not shown).
Therefore, these studies clearly show that Adipoq
2/2 mice
have less fat mass and are resistant to high-fat diet–induced
obesity. Similar phenotypes have been reported by a group
using an independent line of Adipoq
2/2 mice (17). Together,
these data suggest that adiponectin may regulate lipid me-
tabolism in adipocytes.
Triglyceride synthesis and breakdown determine the
volume of lipid droplets and size of adipocytes. Our study
shows that neither adiponectin gene knockout nor over-
expression has any signiﬁcant effect on gene expression of
the key enzymes of triglyceride synthesis in epididymal fat
(Supplementary Fig. 2), which suggests that adiponectin
may regulate lipid metabolism in adipocytes through a
pathway other than de novo lipogenesis.
Adiponectin inhibits lipolysis in mice and cultured
adipocytes. Previous animal studies have clearly demon-
strated that adiponectin reduces circulating FFAs (16,
18–20). Although serum FFA levels at the fed state were
similar between chow-fed Adipoq
2/2 and WT control mice,
prolonged fasting-induced increase of FFA was signiﬁ-
cantly higher in Adipoq
2/2 mice (Supplementary Fig. 3A).
In addition, high-fat diet further increased fasting blood
FFA in Adipoq
2/2 mice (Supplementary Fig. 3B). These re-
sults imply that adiponectin might suppress FFA release
and prompted us to study the effects of adiponectin on
lipolysis in adipocytes.
Initially, we used the selective b3-adrenergic receptor
agonist BRL37344 and Adipoq
2/2 mice to carry out an in
vivo lipolysis study, in which increases of serum free
glycerol were measured to represent hormone-stimulated
lipolysis. As expected, BRL37344 treatment robustly in-
creased serum free glycerol and FFA levels in all mice. The
magnitudes of increase of serum glycerol in Adipoq
2/2
FIG. 1. Adiponectin knockout mice have less body fat and are resistant to high-fat diet–induced obesity. Body composition of chow-fed 2-month-old
male Adipoq
2/2 and WT mice was scanned using EchoMRI (A). Then the mice were fed a high-fat diet (60% of calories from fat). Body weight was
measured weekly (B). Body fat was measured after 8 weeks of high-fat feeding (C). n =8 ,* P < 0.05 vs. high-fat diet–fed Adipoq
2/2 male mice. Data
are expressed as means 6 SEM.
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20 min after BRL37344 injection (P , 0.05, Fig. 2A). Sec-
ond, to avoid inﬂuence from other systems or hormones
that may be rapidly altered by BRL37344 administration, in
vitro lipolysis assays were conducted using epididymal
adipose explants. Results showed that there were no sig-
niﬁcant differences in glycerol release between adipose
explants from Adipoq2/2 and WT control in a basal con-
dition (Fig. 2B). Consistent with the in vivo lipolysis study,
BRL37344-stimulated glycerol releases were remarkably
higher in adipose explants from Adipoq
2/2 mice compared
with WT control mice (P , 0.01, Fig. 2B). In the third
study, lipolysis was assayed in primary mature adipocytes
from Adipoq
2/2 and WT control mice. As shown in Fig. 2C,
basal medium free glycerol levels were similar between
adipocytes from WT control and Adipoq
2/2 mice. How-
ever, in Bt2-cAMP–treated cells, free glycerol levels in the
medium of Adipoq
2/2 adipocytes were twofold higher than
those of adipocytes from WT mice (Fig. 2C). To further
verify the effects of adiponectin on lipolysis, mouse em-
bryonic ﬁbroblast-derived adipocytes from Adipoq
2/2 mice
were treated with or without adiponectin using a transwell
co-culture system. Results showed that cAMP-stimulated
release of glycerol from adiponectin-treated adipocytes
was signiﬁcantly less than from control adipocytes
(Supplementary Fig. 3C). Together, these studies dem-
onstrate that adiponectin inhibits hormone-stimulated li-
polysis in adipocytes.
Adiponectin suppresses HSL activation in adipocytes.
Lipolysis is precisely regulated by hormones, such as glu-
cagon and insulin. However, there was no signiﬁcant differ-
ence in serum glucagon and insulin concentrations between
chow-fed Adipoq
2/2 and WT mice (data not shown), which
prompted us to look at the expression and activation state
of the main lipases in WAT of Adipoq
2/2 mice.
HSL and adipose triglyceride lipase (ATGL) are two
major lipases in adipocytes (21,22). CGI-58 acts as an
ATGL coactivator for lipolysis (23). We examined the ex-
pression and activation status of these lipolytic proteins in
epididymal adipose tissues from mice with adiponectin
gene deletion or overexpression and from cultured adi-
pocytes. For some animal studies, Ad-Acrp30 was used to
reconstitute serum adiponectin in Adipoq
2/2 mice or to
elevate serum adiponectin in C57BL/6 mice. As we pre-
viously reported (18), 3 days after virus injection, total
serum adiponectin protein levels were increased ;12-fold
in C57BL/6 mice, whereas fasting FFA levels were signiﬁ-
cantly reduced (Supplementary Fig. 4A and B). Serum
multimeric adiponectin levels were proportionally ele-
vated, and there were no signiﬁcant changes in insulin
sensitivity, as measured by an insulin challenge test (data
not shown) (18).
As shown in Fig. 3A, there were no signiﬁcant differ-
ences of total protein levels of HSL, ATGL, or CGI-58 in
epididymal fat from Adipoq
2/2, adiponectin-overexpressing,
or adiponectin-reconstituted mice compared with their cor-
responding controls. In addition, adiponectin treatment did
not alter protein levels of HSL, ATGL, or CGI-58 in 3T3-L1
adipocytes (Fig. 3B). These results suggest that adiponectin-
inhibited lipolysis is not through altering HSL, ATGL, or CGI-
58 protein levels in adipocytes.
HSL is the ﬁrst lipase that was found to respond to
lipolytic hormones and hydrolyze triglycerides in adipo-
cytes. PKA plays an essential role in mediating hormone-
stimulated HSL activation and lipolysis in adipocytes. PKA
directly phosphorylates several serine residues in HSL,
including Ser563 and Ser660. However, only Ser660 phos-
phorylation activates HSL, whereas Ser563 phosphoryla-
tion does not correlate with HSL activation (24). By using
phospho-HSL–speciﬁc antibodies, our study showed that
the levels of HSL Ser660 phosphorylation in epididymal fat
from Adipoq
2/2 mice were strikingly elevated compared
with those in WT control mice (P , 0.001, Fig. 3A, bottom
quantiﬁed graphs). In contrast, phosphorylation of HSL
Ser660 was signiﬁcantly suppressed in epididymal fat of the
mice with adenovirus-mediated adiponectin overexpression
FIG. 2. Effects of adiponectin on hormone-stimulated lipolysis in fat
and adipocytes. A: b3-Adrenergic receptor agonist BRL37344 was in-
jected i.p. into 8-week-old male mice, which had been fasted overnight.
Serum free glycerol was measured at the indicated times before and
after the injection. Basal glycerol levels were normalized for the hormone-
stimulated increment calculation. n =6 ,* P < 0.05 vs. WT at the same time
point. B: Epididymal adipose explants were incubated in Dulbecco’s
modiﬁed Eagle’s medium with or without BRL37344 stimulation. Free
glycerol in medium was measured. n =8 ,* P < 0.05 vs. WT adipose
explants with BRL37344 stimulation. C: Primary adipocytes were pre-
pared from epididymal fat of Adipoq
2/2 or WT control mice. Adipocytes
were treated with or without Bt2-cAMP (100 mmol/L) for 1 h. Glycerol
levels in medium were measured. n = 4. Data are presented as mean 6
SEM.
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as i g n i ﬁcantly reduced BRL-stimulated glycerol release was
observed in epididymal adipose explants of mice with
adiponectin overexpression (Supplementary Fig. 5A). In
addition, signiﬁcantly increased HSL Ser660 phosphoryla-
tion was observed in the epididymal fat of Adipoq
2/2 mice
fed a high-fat diet (Supplementary Fig. 5B). These data in-
dicate that HSL activity in WAT is increased in Adipoq
2/2
mice and suppressed in mice with elevated adiponectin. By
using 3T3-L1 adipocytes and co-culture system, our study
further revealed that overnight adiponectin treatment sig-
niﬁcantly decreased both basal and cAMP-stimulated HSL
Ser660 phosphorylation (P , 0.05, Fig. 3B). Together, these
results demonstrate that adiponectin suppresses HSL acti-
vation by reducing Ser660 phosphorylation. However, fur-
ther studies are required to directly verify this.
It has been reported that Ser565 in HSL can be phosphor-
ylated by AMP-activated protein kinase (AMPK), resulting
FIG. 3. Adiponectin inhibits HSL phosphorylation at Ser660. A: Protein samples were prepared from epididymal fat of mice with indicated geno-
types or treatment. Relative protein levels of HSL, ATGL, and CGI-58, and serine phosphorylation levels of HSL were measured by Western blot
using speciﬁc antibodies. For adiponectin overexpression or reconstitution, Ad-Acrp30 or Ad-GFP adenovirus was injected into indicated mice
through the tail vein. Adipose tissues were collected 3 days after injection. n =8 .B: Mature 3T3-L1 adipocytes were co-cultured overnight with
FAO cells transduced with Ad-Acrp30 or Ad-GFP. The insert wells with FAO cells were removed, and adipocytes were treated with Bt2-cAMP for
1h .n =6 .C: Differentiated 3T3-L1 adipocytes were treated with CC (10 mmol/L) and co-cultured with Ad-Acrp30 or Ad-GFP–transduced FAO cells
overnight. Adipocytes were stimulated with Bt2-cAMP for 1 h. n =4 .D: Perilipin A protein levels in epididymal fat from Adipoq
2/2 and WT mice
were measured using Western blotting. n =4 .E: For measuring PKA-phosphorylated perilipin A, perilipin A proteins were immunoprecipitated and
then probed with an antibody against phospho-PKA substrate. n = 6. Data are expressed as means 6 SEM. F: After overnight co-culture with
adiponectin secreting FAO cells and wortmannin (200 nmol/L), 3T3-L1 adipocytes were stimulated with Bt2-cAMP and insulin (25 nmol/L) for 1 h.
Glycerol in medium was measured. n = 4. Data are expressed as means 6 SEM. *P < 0.05 vs. Bt2-cAMP–treated cells.
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AMPK in several tissues (2). We postulated that adipo-
nectin might increase HSL Ser565 phosphorylation via
AMPK to inhibit HSL. To our surprise, HSL Ser565 phos-
phorylation levels neither decreased in Adipoq
2/2 mice nor
increased in adiponectin-overexpressing or -reconstituted
mice compared with their controls (Fig. 3A). These results
exclude the possibility that adiponectin inhibits HSL acti-
vation by increasing HSL Ser565 phosphorylation. To fur-
ther determine the role of AMPK in adiponectin-suppressed
lipolysis, selective AMPK inhibitor Compound C (CC) was
used. Bt2-cAMP–induced glycerol release was signiﬁcantly
higher in CC-treated 3T3-L1 adipocytes (Fig. 3C). However,
CC treatment did not abolish the inhibitory effects of
adiponectin on glycerol release (Fig. 3C). Similar results
were obtained in 3T3-L1CARD1 adipocytes transduced
with adenovirus encoding dominant negative AMPKa (data
did shown). These results do not support any key role of
AMPK in adiponectin-suppressed lipolysis. However, our
study does not completely exclude the involvement of
AMPK in adiponectin-suppressed lipolysis. Apparently, the
underlying mechanisms through which AMPK modulates
lipolysis are far more complicated than a single serine site
phosphorylation in HSL. Studies have shown that PKA or
lipolysis itself induces AMPK activation in adipocytes
(26,27). AMPK activation is required for maximal activation
of lipolysis (26). Furthermore, a recent study reported that
AMPK not only suppresses but also increases lipolysis and
that the effects are dependent on duration of AMPK acti-
vation (28).
Perilipin A is a lipid droplet-binding protein that plays
an important role in lipolysis in adipocytes (29,30). Upon
lipolytic hormone stimulation, PKA-phosphorylated perilipin
A recruits HSL to the lipid droplet surface (31). Our results
showed that perilipin A protein levels in epididymal fat of
Adipoq
2/2 mice were similar to those of WT control mice
(Fig. 3D). There was slightly increased phosphorylation
of perilipin A but without statistical signiﬁcance (Fig. 3E).
These results suggest that PKA-mediated perilipin A phos-
phorylation may be not responsible for adiponectin-inhibited
lipolysis in adipocytes.
Adiponectin sensitizes insulin and insulin inhibits lipol-
ysis (32). This raises the question whether adiponectin
inhibits lipolysis through insulin and whether there is
a synergistic effect. We used the insulin signaling blocker
wortmannin, which abolishes the inhibitory effects of
insulin on lipolysis in adipocytes (32). As expected, wort-
mannin treatment attenuated the inhibitory effects of in-
sulin on glycerol release. However, wortmannin failed to
attenuate adiponectin-suppressed glycerol release (Fig. 3F).
In addition, adipocytes treated with both adiponectin and
insulin did not exhibit a synergistic reduction in glycerol
release. These results suggest that adiponectin inhibits
lipolysis through a pathway other than insulin signaling.
Several adiponectin receptors have been reported (33,34).
AdipoR1 is ubiquitously expressed and is the main adipo-
nectin receptor in white adipocytes (33). To verify whether
adiponectin inhibits HSL activation through the adipo-
nectin receptor, AdipoR1 or siRNA oligo against AdipoR1
was expressed using adenovirus vectors in 3T3-L1CARD1
adipocytes, which express adenovirus receptor to facili-
tate adenovirus-mediated gene transduction in mature
adipocytes (35). Phosphorylation levels of HSL Ser660 at
both basal level and after cAMP stimulation were signiﬁ-
cantly reduced in Ad-AdipoR1–treated cells but were re-
markably increased in AdipoR1 siRNA–treated adipocytes
FIG. 4. Adiponectin reduces PKA RIIa protein levels in adipose tissues and adipocytes. A: Total protein samples were prepared using epididymal
fat from Adipoq
2/2 or Ad-Acrp30–treated mice. B: Fully differentiated 3T3-L1 adipocytes were co-cultured with Ad-Acrp30–transduced FAO cells,
which secrete adiponectin. Protein samples were prepared after 24-h co-culture. Protein levels of PKA subunits were measured by Western blot.
n = 8 for animal study, n = 6 for adipocyte study. Data are expressed as means 6 SEM.
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nectin inhibits HSL Ser660 phosphorylation through
AdipoR1.
Adiponectin inhibits HSL activation through PKA RIIa.
The coordinate changes of HSL Ser660 phosphorylation in
Adipoq
2/2 mice and adiponectin-treated adipocytes suggest
that adiponectin might suppress HSL activation in adipo-
cytes through reducing PKA activity. With the use of an
antibody that recognizes the consensus of phosphorylated
PKA substrate, our study showed that there are signiﬁcant
increases of PKA substrate phosphorylation of proteins in
epididymal fat from Adipoq
2/2mice (Supplementary Fig. 7A),
which further supports the notion that adiponectin inhibits
PKA activation in adipocytes. However, adiponectin gene
deletion has no signiﬁcant impact on total cAMP levels in
WAT (P . 0.05, Supplementary Fig. 7B).
PKA is a holoenzyme containing two regulatory subunits
and two catalytic subunits. PKA type II regulatory subunit
(RII) has two distinct isoforms, RIIa and RIIb. RIIa is
ubiquitously expressed, but RIIb is predominantly expressed
in adipose, brain, and adrenal tissues. RIIb gene knockout
mice are lean and resistant to high-fat diet–induced obesity
(36). We measured the gene expression levels of PKA
catalytic subunits and regulatory subunits RI and RII at
both mRNA and protein levels in epididymal fat from
Adipoq
2/2 and adiponectin-restored mice. There were no
signiﬁcant changes of mRNA levels of the two catalytic
and four regulatory subunits of PKA in Adipoq
2/2 mice
(data not shown). Protein levels of two catalytic subunits,
PKA Ca and Cb, were also similar between Adipoq
2/2 and
WT controls (Fig. 4A). RIIa but not RIIb protein levels
were signiﬁcantly elevated in epididymal fat of Adipoq
2/2
mice (P , 0.05, Fig. 4A). In contrast, adiponectin re-
constitution in Adipoq
2/2 mice remarkably reduced RIIa
in the epididymal fat (P , 0.05, Fig. 4A). A similar in-
hibitory effect of adiponectin on RIIa protein level was
observed in 3T3-L1 adipocytes (P , 0.05, Fig. 4B). These
results led us to hypothesize that reduced RIIa mediates
the inhibitory effect of adiponectin on HSL activation.
To verify this hypothesis, we overexpressed RIIa in
differentiated mature adipocytes. The levels of HSL Ser660
phosphorylation were signiﬁcantly increased in Ad-PKA
RIIa–treated 3T3-L1CARD1 adipocytes (P , 0.05, Fig. 5A)
or OP9 adipocytes (Supplementary Fig. 8). Overexpression
of RIIb even slightly decreased HSL Ser660 phosphorylation
without statistical signiﬁcance (P . 0.05, Supplementary
Fig. 8). Most important, overexpression of RIIa abolished
adiponectin-induced inhibition of HSL Ser660 phosphory-
lation in 3T3-L1CARD1 adipocytes (Fig. 5A). Furthermore,
knocking down RIIa in 3T3-L1CARD1 adipocytes signiﬁ-
cantly reduced both basal and cAMP-stimulated HSL Ser660
phosphorylation (Fig. 5B). These results indicate that adipo-
nectin suppresses HSL activation by reducing RIIa.
Adiponectin reduces PKA RIIa protein level via
proteasomal degradation. The above studies show that
adiponectin reduces RIIa protein levels without altering
RIIa mRNA level. Therefore, we compared the protein
half-life of RIIa between 3T3-L1 adipocytes treated with or
without adiponectin. As shown in Fig. 6A, adiponectin
treatment signiﬁcantly decreases RIIa protein stability. RIIa
protein levels were reduced by 30% after just 1 h of adipo-
nectin treatment in the presence of cycloheximide (Fig. 6B),
which suggests that adiponectin enhances RIIa protein
degradation.
The ubiquitin-dependent proteasome is the most com-
mon system for protein degradation. To further investigate
how adiponectin reduces RIIa, the proteasome-speciﬁc
inhibitor MG-132 was added into medium 30 min before adi-
ponectin treatment. MG-132 completely rescued adiponectin-
induced RIIa reduction in 3T3-L1 adipocytes (Fig. 6C),
which indicates that adiponectin enhances RIIa protein
FIG. 5. PKA RIIa overexpression attenuates the inhibitory effects of
adiponectin on HSL Ser660 phosphorylation. 3T3-L1CARD1 cells were
differentiated into adipocytes. Adenovirus vectors encoding GFP, PKA
RIIa (A), or siRNA against PKA RIIa (B) were added to the medium.
A: Cells were co-cultured 12 h later with Ad-Acrp30–transduced FAO
cells, which secrete adiponectin. B: Some cells were treated with Bt2-
cAMP for 1 h. Protein samples were prepared, and the phosphorylation
levels of HSL Ser660 and other proteins were detected using speciﬁc
antibodies. n = 6. Data are expressed as means 6 SEM. *P < 0.05 vs.
Ad-lacZ siRNA–treated cells at basal state.
ADIPONECTIN AND LIPOLYSIS
1524 DIABETES, VOL. 60, MAY 2011 diabetes.diabetesjournals.orgdegradation through the ubiquitin-proteasome system. Then,
we measured ubiquitin levels of immunoprecipated RIIa
protein from adiponectin-treated and control 3T3-L1 adipo-
cytes. As Fig. 6D shows, the levels of ubiquitinated RIIa
protein were signiﬁcantly elevated in adiponectin-treated
3T3-L1 adipocytes. Together, these results indicate that
adiponectin reduces RIIa protein levels by enhancing
ubiquitin-proteasome–mediated protein degradation. It
should be noted that overall protein ubiquitin levels
were not clearly increased in adiponectin-treated cells
(Supplementary Fig. 9). Similar effects of adiponectin on
overall protein ubiquitination have also been observed in
adiponectin-treated C2C12 myotubes (data not shown).
These results suggest that adiponectin-enhanced RIIa ubiq-
uitination and protein degradation occur in a protein-speciﬁc
manner. The underlying mechanism through which adipo-
nectin enhances RIIa ubiquitination is under investigation.
DISCUSSION
Adipose tissue is the main energy depot in humans and
some animals. During fasting and exercise, triglycerides
are hydrolyzed to release FFAs, which are oxidized by
skeletal muscle, heart, and other tissues as fuel. With the
discovery of adipocyte-derived hormones, the regulatory
role of adipose-derived hormones on lipid metabolism has
FIG. 6. Adiponectin reduces PKA RIIa protein stability. 3T3-L1 cells were differentiated into adipocytes. A: Adipocytes were co-cultured overnight
with Ad-Acrp30–transduced FAO cells. Cycloheximide (100 mg/mL) was added to the medium, and the insert wells with FAO cells were removed.
Protein samples of 3T3-L1 adipocytes were prepared at the indicated time points. B: 3T3-L1 adipocytes were treated with adiponectin-enriched
conditioned medium from Ad-Acrp30–transduced FAO cells. C: Proteasome inhibitor MG132 (25 mmol/L) was added to the medium 30 min before
adiponectin treatment. Protein samples were prepared 2 h later. D: Mature 3T3-L1 adipocytes were co-cultured with adiponectin-expressing FAO
cells for 4 h. The Pierce Crosslink IP kit (Thermo Scientiﬁc Pierce Protein Research Products, Rockford, IL) was used for immunoprecipitation to
eliminate nonspeciﬁc bands. All studies were repeated 4–6 times. The quantiﬁed data are expressed as means 6 SEM. *P < 0.05 vs. control cells at
the same time point (B) or without MG132 treatment (C).
L. QIAO AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, MAY 2011 1525emerged as an important system in maintaining energy ho-
meostasis. Our current study provides strong evidence dem-
onstrating that adiponectin suppresses hormone-stimulated
lipolysis in mouse adipocytes. During the revision of this
article, the same effects of adiponectin on lipolysis were
reported in human adipocytes (37). Therefore, we propose
that adiponectin plays an important role in maintaining
energy homeostasis by suppressing lipolysis in WAT.
It has been reported that leptin, another adipose-derived
hormone, directly increases lipolysis and enhances lipid
depletion from adipocytes (38,39). Although it is uncertain
whether leptin and adiponectin regulate lipolysis through
the same pathway, these studies suggest that adiponectin
and leptin exert opposite regulatory effects on lipolysis in
adipocytes. In addition, the results from cultured adipo-
cytes clearly indicate that adiponectin suppresses lipolysis
through an autocrine loop.
The discovery of the inhibitory effects of adiponectin
on lipolysis will help us to understand how adiponectin
improves circulating lipid proﬁles. However, it is prema-
ture to claim the importance of adiponectin-inhibited li-
polysis in the development of obesity. There is a decrease
of adiponectin gene expression in obesity (2), which
should attenuate the inhibitory effect of adiponectin on
lipolysis, resulting in less lipid storage in fat. Thus, obesity-
associated low adiponectin expression may be beneﬁcial
in the context of obesity. In addition, despite lipolytic
defects that have been observed in obese human and an-
imal models (10,40), the role of lipolytic defects in obesity
is still uncertain. Therefore, more studies are required to
elucidate the role of adiponectin-suppressed lipolysis in the
development of obesity and in energy metabolism under
physiologic conditions.
Plasma FFA inversely associates with insulin sensitivity,
especially in obese subjects (41,42). Our current study
demonstrates that adiponectin inhibits lipolysis in WAT,
which should decrease the level of circulating FFA. There-
fore, we postulate that inhibition of lipolysis and reduction
of FFA is a mechanism through which adiponectin enhances
insulin sensitivity. On the other hand, the insulin-sensitizing
effect of adiponectin may explain how adiponectin sup-
presses lipolysis. However, our study demonstrated that
insulin signaling is not responsible for adiponectin-inhibited
lipolysis in adipocytes. Furthermore, although high-fat
feeding induces more severe insulin resistance in Adipoq
2/2
mice compared with WT control mice (16), the inhibitory
effects of adiponectin on lipolysis are still well preserved.
Therefore, these studies indicate that adiponectin inhibits
hormone-stimulated adipocyte lipolysis through a mecha-
nism(s) other than insulin sensitizing.
The essential role of PKA in mediating hormone-
stimulated lipolysis in adipocytes has been well established.
It has been reported that RIIb gene knockout mice are lean
and resistant to high-fat diet–induced obesity because of
increased locomotor activity, energy expenditure, and li-
polysis in WAT (43–45). Our study showed that adipo-
nectin has no effect on RIIb expression and that RIIb
overexpression even slightly reduces HSL Ser660 phos-
phorylation in adipocytes. The current study does not
provide any evidence to support the involvement of RIIb in
adiponectin-inhibited lipolysis in adipocytes. In contrast,
we found that the protein level of RIIa was elevated in
adiponectin gene knockout mice. Ectopic expression of
RIIa abolished the inhibitory effects of adiponectin on HSL
Ser660 phosphorylation and lipolysis. Conversely, knock-
ing down RIIa reduced both basal and cAMP-stimulated
HSL Ser660 phosphorylation in adipocytes. These results
led us to conclude that reduced RIIa mediates the in-
hibitory effects of adiponectin on lipolysis in adipocytes. It
should be pointed out that by comparing the PKA sub-
strate phosphorylation proﬁle and PKA protein levels be-
tween Adipoq2/2 and WT mice in different tissues (data
not shown), we found that the effects of adiponectin on
PKA subunit expression and PKA activation occur in a
tissue-speciﬁc manner.
The mechanism by which RIIa mediates the inhibitory
effect of adiponectin on lipolysis remains unknown. It is
still incompletely understood how RIIa and RIIb regulate
PKA activity. Because of the large number of substrates
and diverse downstream signaling pathways of PKA,
precise localization of PKA to its speciﬁc substrate by
A kinase-anchoring proteins (AKAPs) has been demon-
strated to be an important mechanism to restrict PKA
action (46). Recent studies revealed that RIIa binds
tightly with some AKAPs and plays an important role in
compartmentalizing cAMP/PKA signal transduction (46–48).
We postulate that adiponectin suppresses RIIa expres-
sion, which may shift AKAPs/PKA away from the com-
partment where HSL localizes, resulting in decreased
HSL phosphorylation and activation. The absence of effect
of adiponectin on perilipin A phosphorylation also supports
this postulation.
In conclusion, our study demonstrates that adiponectin
inhibits lipolysis and directly regulates lipid metabolism in
adipocytes. Our data also suggest that adiponectin sup-
presses triglyceride hydrolysis by inhibiting PKA-induced
HSL activation.
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